Background and objectives Uromodulin-associated kidney disease (UAKD) is an autosomal dominant disease caused by uromodulin (UMOD) gene mutations. This study explored genotype-phenotype correlations by examining the relationship between the type of UMOD mutation and the age at onset of ESRD.
Introduction
Uromodulin (UMOD) is encoded by the UMOD gene on chromosome 16p12 and is the most abundant protein found in human urine (1) . UMOD is postulated to affect urine concentration by maintaining tubular water impermeability and regulating salt transport (2, 3) . More recent research suggests it can also activate dendritic cells to express proinflammatory cytokines and thereby possibly promote inflammation in the renal interstitium (4) . Uromodulin-associated kidney disease (UAKD) refers to autosomal dominant interstitial kidney disease. Mutations in the UMOD gene were found to be associated with clinical manifestations, such as hyperuricemia, gout, and CKD (5) . Different diagnoses were given to patients with these conditions, which were also found to have mutations in the UMOD gene (e.g., medullary cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy, hereditary nephropathy with hyperuricemia and gout, uromodulin storage disease, and glomerulocystic kidney disease). However, it has been proposed that a clinical distinction among these terms is not warranted because they appear to represent a spectrum of one and the same disease (6) . UMOD is first synthesized as an 84-kD precursor, then slowly converted into the mature 95-kD 640-amino acid glycoprotein. UMOD mutations present in patients with UAKD cause a delay in the maturation rate and protein export to the plasma membrane because of a longer retention time in the endoplasmic reticulum (7) (8) (9) (10) (11) (12) . It is possible that mutations that differentially affect the rate of UMOD maturation and expression on the cellular membrane can influence the clinical course of the disease. Most UMOD mutations cluster in exons 4 and 5 and cause changes to cysteine residues, which leads to a misfolding of the UMOD molecule (1) .
UMOD contains three epidermal growth factor (EGF) domains; a cysteine-rich region, which includes a domain of eight cysteines (D8C); and a zona pellucida domain (12) (Supplemental Figure 1 and Supplemental Table 1 ). Exons 4 and 5 encode the first EGF domain to the end of the cysteine-rich region. Mutations in each region have been found with varying levels of clinical phenotype severity. Mutations that reduce the calcium-binding affinity in the calcium-binding EGF (cbEGF) domain may impair global protein structure (7) . Bound calcium stabilizes
Materials and Methods

Search Strategy
Extensive electronic and manual bibliographic research was performed to ascertain patient-level data of all cases of UAKD published through October 2011. Meticulous care was exercised to exclude duplicate reports of patients. We reviewed citations in English from PubMed, the D. Samuel Gottesman Library from the Albert Einstein College of Medicine in New York, and Google Scholar. The search strategy included keywords and synonyms for the following terms: familial juvenile hyperuricemic nephropathy, uromodulin, Tamm-Horsfall protein, medullary cystic kidney disease, mutation, uric acid, gout, and hyperuricemia. Full-text articles were retrieved for further independent manual evaluation by two authors (J.M. and E.V.). Supplemental searches using the names of authors of relevant articles were performed.
All retrieved published full-text case studies on individuals and families with UAKD were included. When the same family was investigated in more than one study, the most recent study with the most thorough data were included. If the most recent publication had incomplete clinical data, the data were combined with a previous study and adjusted for time. In some instances, authors were personally contacted for data verification. In addition, one hitherto unpublished UAKD family was included. A search for UMOD mutations in the 1000 Genomes database showed that UAKD-associated mutations were not detected in that population, confirming the rare, pathogenic nature of the UMOD mutations studied here. Allele frequency variation across different populations is therefore an unlikely confounding factor.
Data Ascertainment
Articles were scanned for information on all patients reported. All clinical data were recorded in a database, including pedigree position, sex, race, country of residence, type of UMOD mutation, ESRD status, age at hyperuricemia, gout, ESRD, death, and age at last follow-up. Not every article had information on every category; reports that lacked information on the UMOD mutation or ESRD status were excluded. UMOD cell surface expression data were taken from respective reports (8) (9) (10) 12, 15) and calculated as percentage of wild-type expression; a cutoff of 50% was used to separate UMOD mutations into two groups (high versus low expression). ESRD was defined as the initiation of dialysis therapy, renal transplantation, or death from renal failure in the absence of renal replacement therapy initiation. Age at hyperuricemia onset was defined as first diagnosis of serum uric acid level .1 SD greater than normal values for age and sex (16) . Age at gout onset was defined as the patient's age at the first episode of gouty arthritis.
Statistical Analyses
The primary aim of the study was to explore the relationship between UMOD mutations and time to ESRD. Secondary aims were to analyze the relationships between sex and age at the onset of hyperuricemia and gout. To that end, median age at the onset of hyperuricemia, gout, and ESRD were computed. In separate analyses, patients were stratified by sex, presence or absence of hyperuricemia or gout, UMOD mutation, affected uromodulin domain, and cell surface expression pattern.
The six UMOD mutations with the most affected individuals were examined to determine whether having a different genotype could affect the outcome. In an additional analysis, UMOD mutations were aggregated according to their place within one of the five following functional domains: CysRich-1, CysRich-2, D8C, EGF2, and EGF3. Only functional domains with mutations affecting more than 14 patients were considered. Mutations were further classified into groups in which substitutions affected a cysteine residue, a nonpolar residue, and a noncysteine polar residue. Cysteine substitutions were then compared with noncysteine substitutions.
For the modeling process, statistical adjustments for members of the same family were made. This was done by multiplicatively adjusting the hazard rate of each family member by the same factor (the frailty) according to the model mentioned below. For example, it may be the case that all members of family A are frailer than members of family B, adjusting for other covariates. In this case, the family A frailty will be greater than the family B frailty.
The gamma shared frailty model-which is an extension of the Cox model-was used to estimate hazard ratios (17, 18) . If the frailty effect was not statistically significant at 0.05, it was excluded and a conventional Cox proportional hazard model was used to fit to the data. The R package survival was used to fit the models and perform hypothesis testing (19) .
Additionally, in models with significant frailty effect, the shared frailty model was used to estimate median time to event and the 95% confidence interval (CI) around the median. The median can be computed for any given frailty, and here a value of unity was used (this assumes that the individual has average frailty). For case frailty = 1, the formula for the median under the shared frailty model is the same as the formula for the median under the Cox model, but the latter must use the parameter estimates from the former.
A formula for computing CIs around the median based on a shared frailty model is not known, and so a bootstrap approach was used. This involved building 500 resamples drawn with replacement from the original dataset. However, care was taken with building these resamples; when a subject was queried and added to the database, further information about family members was requested to be provided as well. A simple bootstrap that would randomly sample patients from the database would lose this family structure, and so a block bootstrap was performed. In Table 1 . Characteristics of patients with UMOD (36) 1 (31) 3 (22) c.A383G
p.Asn128Ser particular, sampling was done at the family level, and the sample was constructed by adding random families until the size of the resampled dataset matched the size of the original dataset. The rule used was that so long as the number of patients in the resampled set was less than the number in the original set, another family was added. Next, the median time to event was computed for each resampled dataset according to the procedure discussed above, and 2.5th and 97.5th quantiles of the distribution were determined. When the frailty effect was not significant, the median time to event and 95% CI were estimated from KaplanMeier curves.
Results
We ascertained 202 patients from 74 UAKD families. Overall, 59 different UMOD mutations were found in patients from 25 countries (Table 1) . Sixty-eight of these 202 patients (33%) had ESRD. The presence or absence of hyperuricemia was reported in 166 patients, of whom 151 had hyperuricemia (91%). Gout was present in 86 of 179 patients with recorded gout status (48%). In the whole cohort, the median ages at onset of hyperuricemia, gout, and ESRD were 24.0 (95% CI, 19.3 to 28.7), 40.0 (95% CI, 32.1 to 47.9), and 56.0 (95% CI, 52.0 to 60.0) years, respectively.
Relationship between Sex, Hyperuricemia, Gout, and ESRD Sex was not associated with age at diagnosis of hyperuricemia (Table 2) . However, men developed gout at an earlier age (P=0.02; hazard ratio, 2.28 by the shared frailty model). Men experienced ESRD at a younger age than did women (50 years for men and 60 years for women; P=0.04 by the shared frailty model). Neither hyperuricemia nor gout was associated with age at ESRD onset (Table 3) .
Relationship between UMOD Mutations and ESRD
Thirty-two of the 59 (54%) UMOD mutations affected a cysteine residue. Because of the small number of affected patients in most of the mutations, only the relationship between the six most prevalent UMOD mutations (i.e., with the most affected individuals) and ESRD was examined. UMOD mutations were related to age at ESRD onset Summary of all uromodulin mutations found with their corresponding family, functional domain, exon, demographics, morbidity, and mean age at first diagnosis with hyperuricemia, gout, and renal failure. For each mutation, nucleotide numbering reflects cDNA numbering with 1 = A of the ATG translation initiation codon, followed by its amino acid change. If the cDNA sequence of a reported mutation was based on another template, it was converted to the 1 = A of ATG notation in the Gender was not reported in all family members. Cox proportional hazards analysis of the association of sex on time to hyperuricemia, gout, and ESRD fitted with a shared frailty model.
(P,0.001; log-rank test) ( Table 4 and Figure 1 ). Patients with the p.Cys77Tyr mutation had the youngest mean manifestation age of ESRD (37.4 years), and patients with the p.Gln316Pro mutation were at the other extreme (65.5 years) ( Table 5) .
Relationship between Outcome and Uromodulin Domain, Surface Expression, and Altered Amino Acid of UMOD Mutation The effects of mutations in different locations within the UMOD protein domains were investigated (Supplemental Table 1). Onset of ESRD was significantly affected by the amino acid sequence alterations in certain UMOD domains (Table 6) . Mutations in the first cysteine-rich region (Cys-Rich 1) had the longest median time to ESRD at 65.0 years, whereas patients with mutations affecting the second calciumbinding EGF domain (cbEGF2) experienced ESRD onset at the youngest age of 45.0 years (Table 7) . Mutations affecting EGF domains 2 or 3 were associated with earlier development of ESRD compared with mutations affecting the other UMOD domains (Table 7) .
Previous reports on UMOD in vitro cell surface expression with regard to UMOD mutation allowed us to investigate this aspect in our study. In vitro cell surface expression compared with wild type was assessed for 15 UMOD mutations (Supplemental Table 2 ) to determine whether the maturation/export rate of the UMOD correlates with clinical phenotypes. When we compared UMOD mutations associated with low cell surface expression (,50%) to those with high expression (.50%), we found no association with the age at onset of ESRD. Median age at ESRD was 59 years for patients with mutations with low in vitro UMOD expression and 56 years for those with high expression.
The type of amino acid (polar, nonpolar, and cysteine) affected by a UMOD mutation was also analyzed. The type of amino acid affected was not a significant factor in determining onset of ESRD by the shared frailty model (Supplemental Table 3 , A and B).
Discussion
Our analysis indicates that the type of UMOD mutation affects the clinical phenotype of patients with UAKD, in particular the age at onset of ESRD. Patients with the p. Cys77Tyr UMOD mutation experienced ESRD almost 30 years earlier than patients with p.Gln316Pro. To the best of our knowledge, this report compiles results from the most comprehensive and geographically diverse database of patients with UAKD. Recognizing that within-family correlations may bias any analysis of genotype-phenotype relationships, we used Cox proportional hazards models fitted with shared gamma frailty terms to adjust for within-family correlations whenever analyses encompassed multiple families lumped together in a single category. Our results are similar to those of a recent study that found 37 UMOD mutations in 109 patients from 45 families, in which median time to ESRD was determined to be 54.0 years (20) . This study by Bollée et al. was actually published after we closed our database; therefore, patients from this study were not included in our analysis.
Sex was significantly associated with onset of ESRD, with men developing ESRD at a younger age. Although men and women developed hyperuricemia at approximately the same age, men experienced gout at a younger age. Gout is generally rare in young women (21) . However, women with UMOD mutations still often have gout even though they develop it later than men. Gout is more prevalent in men in the general population, possibly because of lower fractional uric acid excretion (FEUA) in men. In patients with UAKD, FEUA is reduced to approximately equal levels in men and women (9) , suggesting that hyperuricemia due to low FEUA is not the only reason for the earlier occurrence of gout in men than women.
The significant association of different UMOD domain mutations with age at onset of ESRD indicates that the location of the mutation can affect the progression of renal disease. The median age at ESRD development was lowest in patients with mutations in the EGF2 and EGF3 domains. Time to renal failure was longest in patients with UMOD mutations located in the domain of eight cysteines (D8C) and the cysteine-rich regions (Cys-Rich 1 and Cys-Rich 2).
Our analysis indicates that individuals with UAKD often develop hyperuricemia in their early twenties. Men develop gout in their early thirties and women, in their early forties. Finally, ESRD ensues in the mid-fifties. Of note, development of hyperuricemia and gout does not predict the age at which a patient will reach ESRD. It is clinically important to appreciate that ESRD can still develop without the previous occurrence of hyperuricemia or gout. The level of in vitro cell surface expression of mutated UMOD was not associated with the median age at ESRD. This is contrary to what we expected because cellular retention and reduced secretion of UMOD is thought to exert harmful effects. The findings open the intriguing possibility that greater secretion of mutated UMOD may actually be more damaging than retention of the mutated protein. This notion is in line with the observation that elevated urinary uromodulin concentrations precede the onset of CKD and are associated with a common polymorphism in the UMOD region (22) . The adjusted odds ratio of CKD was found to be 1.72 per 1-SD higher uromodulin level. Intracellular accumulation of UMOD in cell models has been associated with cell apoptosis (23) . Evidence for a proteotoxic effect of mutant UMOD expression has not been observed with use of different kidney cell lines under basal or stressed conditions (15) . Furthermore, the lack of correlation between presence of hyperuricemia or gout and time to ESRD suggests that different mechanisms may be responsible for the development of ESRD and development of hyperuricemia or gout in these patients.
In one study, not only were the p.Cys77Tyr and p. Asn128Ser mutants secreted less than the wild type in transfected LLC-PK1 cells, but that secretion was also reduced at the apical membrane and increased at the basolateral membrane (15) . UMOD secreted into the renal interstitium may stimulate immune cells, leading to inflammation and progression of tubulo-interstitial damage (15) . This finding thereby suggests that the direction of UMOD secretion and the degree of UMOD retention/ secretion may be relevant in the development of clinical phenotypes.
It is unclear whether allopurinol therapy can slow progression of renal disease. Some reports indicate that allopurinol can slow down progression of kidney disease (24, 25) , whereas others state that it will treat only hyperuricemia and gout, without any effect on renal diagnosis (26) . Because drug therapy has been reported in only a few patients, our data cannot answer the central question of whether allopurinol helps prevent or delay ESRD. Further studies on that subject are needed. Results of the Kaplan-Meier analysis of the six most prevalent UMOD mutations. Mean age at manifestation of ESRD was calculated. The SEM and 95% confidence interval were also calculated for each mutation. Time to ESRD was significantly different between the mutations (P,0.001).
Obvious limitations of our study are underreporting of cases and lack of complete data because many reports did not include all the key clinical data from each patient. Complete data could not be included for every patient because many patients died before any genetic analysis could be done; for others, the information was difficult to obtain from the relatives. Because the main research question was the relationship between UMOD genotype and ESRD, we limited our analysis to patients with determined or inferred UMOD genotype, known ESRD status, and age at ESRD onset. Despite these limitations, our database, which is available to researchers and clinicians upon request, may prove to be a valuable resource for future research in UMOD-related disorders.
In conclusion, certain UMOD genotypes are associated with an earlier onset of ESRD. UMOD mutations affecting different protein domains vary in their clinical correlates, with mutations affecting EGF domains being associated with the most severe clinical phenotypes. Hyperuricemia and gout did not predict the advent of ESRD. Mutations with high or low in vitro UMOD cell membrane expressions were not associated with time to ESRD. This retrospective study could not explore the relevance of factors related to environment and lifestyle on clinical outcomes; this topic will require prospective studies. The median manifestation age of ESRD was calculated according to the shared frailty model. The 95% confidence interval was also calculated for each functional domain whenever possible. Cys-Rich2, cysteine-rich domain; NA, not available; D8C, domain of eight cysteines; EGF, epidermal growth factor.
